Clinical Trials for Non-Small Cell Lung Cancer

8 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
Basic ScienceVICCTHN1164
11/04/2011
Molecular Profiles for Lung Cancer Pathogenesis and Detection
Basic ScienceVICCTHO0547
12/19/2005
Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy (SPORE)
TreatmentVICCTHN12106
03/12/2014
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
TreatmentVICCTHN1307
06/06/2013
A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations
TreatmentVICCTHN1242
10/24/2012
A Phase IB, Multi-Center,Open-Label Study of the MTOR Kinase Inhibitor CC-223 in Combination with Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
TreatmentECOGTHNE5508
06/29/2011
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Premetrexed, or Combination of Bevacizumab and Premtrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
TreatmentECOGTHO5508-M
02/09/2011
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
TreatmentECOGTHOE1505-M
07/27/2007
A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)

You do not have JavaScript enabled. This site works better with JavaScript turned on.